Results 121 to 130 of about 23,888,926 (291)
A novel neutrophil‐hitchhiking, rocket‐inspired nanoplatform is developed to cross the blood‐brain barrier for sequential, spatiotemporal drug delivery. By responsive surface transformation in the ischemic penumbra, it precisely targets mitochondria to suppress Drp1‐mediated fission.
He Bai +17 more
wiley +1 more source
Pharmaceutical industry and regulatory agencies consider mathematical modeling as a valuable tool to increase the productivity of pharmaceutical research and the efficiency of new drug development processes.
Savoca A. +5 more
core +1 more source
Rhoifolin directly targets NMNAT1, thereby activating nicotinamide salvage pathway and promoting intracellular NAD+ biosynthesis. Elevated NAD+ levels enhance SIRT1 activity, leading to FOXO1 deacetylation and nuclear translocation. Nuclear FOXO1 subsequently binds to the IL‐22 promoter, upregulating IL‐22 transcription and potentiating ILC3 effector ...
Hongqiong Yang +12 more
wiley +1 more source
The Gela/decitabine/La2(CO3)3 colloidal (GDLC) hydrogel developed here could reverse the epigenetic silencing of the GSDME gene by the synergistic interaction between DAC and La3+, while concurrently activating caspase‐3, thus facilitating pyroptosis induction under the tumor microenvironment.
Yang Hong +6 more
wiley +1 more source
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu +9 more
wiley +1 more source
Therapeutic oligonucleotides (TOs) represent an emerging modality, which offers a promising alternative treatment option, particularly for intracellular targets.
Felix Stader +5 more
doaj +1 more source
IntroductionCritically ill patients show large variability in drug disposition due to e.g., age, size, disease and treatment modalities. Physiologically-based pharmacokinetic (PBPK) models can be used to design individualized dosing regimens taking this ...
Joyce E. M. van der Heijden +7 more
doaj +1 more source
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou +14 more
wiley +1 more source
Buprenorphine readily crosses the placenta, and with greater prenatal exposure, neonatal opioid withdrawal syndrome (NOWS) likely grows more severe. Current dosing strategies can be further improved by tailoring doses to expected NOWS severity.
Matthijs W. van Hoogdalem +7 more
doaj +1 more source
The appropriate use of antibiotics is crucial and involves selecting an optimal dosing regimen based on pharmacokinetic (PK) and pharmacodynamic (PD) indicators.
Ryota Tanaka, Kei Irie, Tomoyuki Mizuno
core +1 more source

